Recent Advances in Pediatrics

Walsh-Sukys MC. Persistent pulmonary hypertension of the newborn. Clin Perinatol 1993;20:20-127.

Gibaldi M. What is nitric oxide and why are so many people studying it? J Clin Pharmacol 1993;33:33-488.

Ignarro LJ. Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989;65:65-1.

Pepke-Zaba J , Higenbottam TW , Dinh-Xuan AT , Stone D , Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991;338:338-1173.

Kinsella JP , Neish SR , Shaffer E , Abman SH. Low-dose inhalational nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:340-819.

Roberts JD , Polaner DM , Lang P , Zapol WM. Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. Lancet 1992;340:340-818.

Kinsella JP , Neish SR , Ivy DD , Shaffer E , Abman SH. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. J Pediatr 1993;123:123-103.

Kinsella JP , Toews WH , Henry D , Abman SH. Selective and sustained pulmonary vasodilation with inhalational nitric oxide therapy in a child with idiopathic pulmonary hypertension. J Pediatr 1993;122:122-803.

Abman SH , Kinsella JP , Schaffer MS , Wilkening RB. Inhaled nitric oxide in the management of a premature newborn with severe respiratory distress and pulmonary hypertension. Pediatrics 1993;92:92-606.

Geggel RL. Inhalational nitric oxide: a selective pulmonary vasodilator for treatment of persistent pulmonary hypertension of the newborn. J Pediatr 1993;123:123-76.

Shaffer TH , Cox C , Wolfson MR. Wave of the future. J Resp Care Pract 1993;6:6-22.

Jacobs HC , Mercurio MR. Perfluorocarbons in the treatment of respiratory distress syndrome. Semin Perinatol 1993;17:17-295.

Leach CL , Fuhrman BP , Morin FC , Rath MG. Perfluorocarbon-associated gas exchange (partial liquid ventilation) in respiratory distress syndrome: a prospective, randomized, controlled study. Crit Care Med 1993;21:21-1270.

Notterman DA. A new PAGE in mechanical ventilation? Crit Care Med 1993;21:21-1257.

Greenspan JS , Wolfson MR , Rubenstein SD , Shaffer TH. Liquid ventilation of human preterm neonates. J Pediatr 1990;117:117-106.

Chan GLC , Gruber SA , Skjei KL , Canafax DM. Principles of immunosuppression. Crit Care Med 1990;6:6-841.

Barry JM. Immunosuppressive drugs in renal transplantation: a review of the regimens. Drugs 1992;44:44-554.

Kahan BD. Cyclosporine. N Engl J Med 1989;321:321-1725.

Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991;13:13-465.

Awani WM. Pharmacodynamic monitoring of cyclosporine. Clin Pharmacokinet 1992;23:23-428.

Yee GC. Recent advances in cyclosporine pharmacokinetics. Pharmacotherapy 1991;11(suppl):13S-34S.

Sokol RJ , Johnson KE , Karrer FM , Narkewicz MR , Small D , Kam I . Improvement of cyclosporine absorption in children after liver transplantation by means of water-soluble vitamin E. Lancet 1991;338:338-212.

Hanson JS , McCallum RW. The diagnosis and management of nausea and vomiting: a review. Am J Gastroenterol 1985;80:80-210.

Andrews PLR , Davis CJ , Bingham S , Davidson HIM , Hawthorn J , Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol 1990;68:68-325.

Bradley PB , Engel G , Feniuk W , Fozard JR , Humphrey PP , Middlemiss DN . Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 1986;25:25-563.

Van Harten J. Clinical pharmacokinetics in selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:24-203.

Figg WD , Graham CL , Hak LJ , Dukes GE. Ondansetron: a novel antiemetic agent. South Med J 1993;86:86-497.

Markham A , Sorkin EM. Ondansetron: an update of its therapeutic use in chemotherapy-induced and postoperative nausea and vomiting. Drugs 1993;45:45-931.

Sage TA , Jones WN , Clark RF. Ondansetron in the treatment of intractable nausea associated with theophylline toxicity. Ann Pharmacother 1993;27:27-584.

Reed MD , Marx CM. Ondansetron for treating nausea and vomiting in the poisoned patient. Ann Pharmacother 1994;28:28-331.

Mitchelson F. Pharmacological agents affecting emesis: a review. Drugs 1992;43:43-295 (pt. 1), 443–63 (pt. 2).

Kris MG , Gralla RJ , Clark RA , Tyson LB. Dose-ranging evaluation of the serotonin antagonist (GR38032F) when used as an antiemetic in patients receiving anti-cancer chemotherapy. J Clin Oncol 1988;6:6-659.

McQueen KD , Milton JD. Multicenter postmarketing surveillance of ondansetron therapy in pediatric patients. Ann Pharmacother 1994;28:28-85.

Ballatori E , Roila F , Berto P , De Angelis V , Neri C . Cost and cost-effectiveness analysis of ondansetron versus metoclopramide regimens: a hospital perspective from Italy. Pharmacoeconomics 1994;5:5-227.

Borys DJ , Setzer SC , Ling LF , Reisdorf JJ , Day LC , Krenzelok EP. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992;10:10-115.

Hsu VD. Sumatriptan: a new drug for vascular headache. Clin Pharm 1992;11:11-919.

Solomon GD. Therapeutic advances in migraine. J Clin Pharmacol 1993;33:33-200.

National Cholesterol Education Program (NCEP). Highlights of the Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:89-495.

Benuck I , Gidding SS , Donovan M , Traisman HS. Usefulness of parenteral serum total cholesterol levels in identifying children with hypercholesterolemia. Am J Cardiol 1992;69:69-713.

McEvoy GK , ed. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists, 1993;1011–5, 1018–21.

Liacouras CA , Coates PM , Gallagher PR , Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr 1993;122:122-477.

Becker M , Staab D , Von Bergmann K. Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate. Pediatrics 1992;89:89-138.

Committee on Infectious Disease, American Academy of Pediatrics. Haemophilus influenzae type b conjugate vaccines: recommendations for immunization with recently and previously licensed vaccines. Pediatrics 1993;92:92-480.

Progress toward elimination of Haemophilus influenzae type b disease among infants and children—United States, 1987–1993. MMWR Morb Mortal Wkly Rep 1994;43:43-144.

Paradiso PR , Hogerman DA , Madore DV , Keyserling H , King J , Reisinger KS . Safety and immunogenicity of a combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccine in young infants. Pediatrics 1993;92:92-827.

King GE , Hadler SC. Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis J 1994;13:13-394.

Pertussis vaccination: acellular pertussis vaccine for reinforcing and booster use—supplementary Immunization Practices Advisory Committee (ACIP) statement. MMWR Morb Mortal Wkly Rep 1992;41:41-1.

Committee on Infectious Diseases. American Academy of Pediatrics. Universal hepatitis B immunization. Pediatrics 1992;89:89-795.

Goldfarb J , Baley J , Medendorp SV , Seto D , Garcia H , Toy P . Comparative study of the immunogenicity and safety of two dosing schedules of Engerix-B hepatitis B vaccine in neonates. Pediatr Infect Dis J 1994;13:13-18.

Kuter BJ , Weibel RE , Guess HA , Matthew H , Morton DH , Neff BJ . Oka/Merck varicella vaccine in healthy children: final report of a 2-year efficacy study and 7-year follow-up studies. Vaccine 1991;9:9-443.

Bernstein HH , Rothstein EP , Watson BM , Reisinger KS , Blatter MM , Wellman CO . Clinical survey of natural varicella compared with breakthrough varicella after immunization with live attenuted Oka/Merck varicella vaccine. Pediatrics 1993;92:92-833.

Lieu TA , Cochi SL , Black SB , Halloran ME , Shinefield HR , Holmes SJ . Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 1994;271:271-375.